SK283883B6 - Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok - Google Patents

Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok Download PDF

Info

Publication number
SK283883B6
SK283883B6 SK1307-97A SK130797A SK283883B6 SK 283883 B6 SK283883 B6 SK 283883B6 SK 130797 A SK130797 A SK 130797A SK 283883 B6 SK283883 B6 SK 283883B6
Authority
SK
Slovakia
Prior art keywords
fumagillol
active ingredient
preparation
medicaments
milligrams
Prior art date
Application number
SK1307-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK130797A3 (en
Inventor
Jean-Michel Molina
Francis Derouin
Original Assignee
Sanofi-Synthelabo
Assistance Publique- Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo, Assistance Publique- Hopitaux De Paris filed Critical Sanofi-Synthelabo
Publication of SK130797A3 publication Critical patent/SK130797A3/sk
Publication of SK283883B6 publication Critical patent/SK283883B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
SK1307-97A 1995-03-27 1996-03-26 Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok SK283883B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
SK130797A3 SK130797A3 (en) 1998-03-04
SK283883B6 true SK283883B6 (sk) 2004-04-06

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1307-97A SK283883B6 (sk) 1995-03-27 1996-03-26 Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok

Country Status (25)

Country Link
US (1) US5900431A (is)
EP (1) EP0817626B1 (is)
JP (1) JP3260378B2 (is)
KR (1) KR100286920B1 (is)
CN (1) CN1072485C (is)
AP (1) AP646A (is)
AT (1) ATE172641T1 (is)
AU (1) AU706161B2 (is)
CA (1) CA2216623C (is)
CZ (1) CZ286821B6 (is)
DE (1) DE69600879T2 (is)
DK (1) DK0817626T3 (is)
EA (1) EA000150B1 (is)
ES (1) ES2128846T3 (is)
FR (1) FR06C0014I2 (is)
HU (1) HU224028B1 (is)
IS (1) IS2048B (is)
NO (1) NO315968B1 (is)
NZ (1) NZ304906A (is)
OA (1) OA10515A (is)
PL (1) PL183378B1 (is)
SK (1) SK283883B6 (is)
TR (1) TR199701048T1 (is)
UA (1) UA41446C2 (is)
WO (1) WO1996030010A2 (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ATE361757T1 (de) 1999-02-26 2007-06-15 Sanofi Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
EP2217283A2 (en) * 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
NZ590732A (en) * 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (es) 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
MX2013005208A (es) 2010-11-09 2013-08-01 Zafgen Inc Sólidos cristalinos de un inhibidor de metionina aminopeptidasa 2 y métodos para obtener y usar los mismos.
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
KR20140112565A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2013259760A1 (en) 2012-05-07 2014-11-20 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
SG11201503521QA (en) 2012-11-05 2015-06-29 Zafgen Inc Methods of treating liver diseases
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
CA2904353A1 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
KR100286920B1 (ko) 2001-04-16
IS2048B (is) 2005-09-15
EA000150B1 (ru) 1998-10-29
CZ286821B6 (en) 2000-07-12
WO1996030010A2 (fr) 1996-10-03
CN1179715A (zh) 1998-04-22
CZ304997A3 (en) 1997-12-17
NO315968B1 (no) 2003-11-24
EP0817626A2 (fr) 1998-01-14
OA10515A (fr) 2002-04-24
CA2216623C (en) 2005-05-31
TR199701048T1 (xx) 1998-01-21
DE69600879D1 (de) 1998-12-03
US5900431A (en) 1999-05-04
UA41446C2 (uk) 2001-09-17
CN1072485C (zh) 2001-10-10
HU224028B1 (hu) 2005-05-30
MX9707150A (es) 1998-07-31
WO1996030010A3 (fr) 1996-11-28
SK130797A3 (en) 1998-03-04
DK0817626T3 (da) 1999-07-12
FR06C0014I1 (is) 2006-11-17
IS4557A (is) 1997-09-11
NO974466L (no) 1997-09-26
JP3260378B2 (ja) 2002-02-25
NO974466D0 (no) 1997-09-26
ATE172641T1 (de) 1998-11-15
AU706161B2 (en) 1999-06-10
FR06C0014I2 (is) 2006-12-29
JPH11506421A (ja) 1999-06-08
AU5278696A (en) 1996-10-16
HUP9801220A2 (hu) 1999-09-28
HUP9801220A3 (en) 2001-10-29
NZ304906A (en) 1999-06-29
AP9701092A0 (en) 1997-10-31
ES2128846T3 (es) 1999-05-16
PL322470A1 (en) 1998-02-02
KR19980703271A (ko) 1998-10-15
EP0817626B1 (fr) 1998-10-28
DE69600879T2 (de) 1999-06-02
EA199700267A1 (ru) 1998-04-30
PL183378B1 (pl) 2002-06-28
AP646A (en) 1998-04-27
CA2216623A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
SK283883B6 (sk) Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
RU2197233C2 (ru) Применение кислых алкилфумаратов для лечения псориаза, псориатического артрита, нейродермита и регионального энтерита крона
EP0264187B1 (en) Pharmaceutical composition containing ibuprofen and aluminium hydroxide
US7749987B2 (en) Contraception method
JPH0774155B2 (ja) 消炎作用を示す計画的放出型経口投与用医薬製剤
US4588589A (en) Antidiarrheal compositions and use thereof
DE3834794C2 (is)
DE19858789A1 (de) Kombination von Cerivastatin und Fibraten
CA2136977A1 (en) _-8-tetrahydro-cannabinol as antiemetic
US4701446A (en) Pyrethroid containing pharmaceutical compositions
IL126199A (en) Pharmaceutical preparation for administration through the nose for preventive treatment for delayed vomiting
US4064230A (en) Polyenic macrolide compositions
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
EP0003750B1 (de) Salze von Dithiodialkansulfonsäuren zur Verwendung bei der cytostatischen Therapie mit Alkylantien
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
IE900306A1 (en) Agent for use in the prevention, control or reversal of¹hypertension
Chang et al. Activity of roxithromycin against Toxoplasma gondii in murine models
US4237159A (en) Novel anti-inflammatory composition
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
FR2566664A1 (fr) Composition utile au traitement de la diarrhee contenant du dextromethorphan
JPS63258421A (ja) 糖ラクタムを含有する抗炎症剤
Romankiewicz Factors Influencing Renal Distribution of Antibiotics a Key to Therapy of Pyelonephritis

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20160326